Safety assessment of Aflibercept injection in Japanese patients with neovascular glaucoma
Official title: Drug Use Investigation for Eylea for Neovascular Glaucoma (NVG)
Run by Bayer · NCT04519619 · Data updated 2026-11-12
This study is testing if Aflibercept can safely help Japanese patients with neovascular glaucoma over six months.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 480 (estimated) |
| Sponsor | Bayer Industry-sponsored |
| Locations | 1 site (Multiple Locations) |
| Status | Recruiting |
| Started | November 27, 2020 |
| Main results expected | June 30, 2027 |
| Study ends | June 30, 2028 |
| Registry record updated | June 30, 2026 |
| Trial ID | NCT04519619 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are Japanese patients diagnosed with neovascular glaucoma who have received Aflibercept treatment.
✕Probably not a fit
Patients with contraindications to Aflibercept or those diagnosed with other indications may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the safety and effectiveness of Aflibercept (Eylea) in treating Japanese patients diagnosed with neovascular glaucoma. It will involve a multi-center approach, where 480 patients will be recruited and followed for six months after starting treatment. Data will be collected through routine clinical visits, allowing investigators to monitor patient outcomes in real-world settings. The study is designed to provide insights into the safety profile of Eylea as used in clinical practice.
Why it matters
Potential benefit: If successful, this study could enhance understanding of the safety and effectiveness of Eylea for patients with neovascular glaucoma.
How similar studies have gone: While this study is observational, similar studies assessing the safety of Aflibercept have shown promising results in other populations, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of NVG * Patients who have received IVT-AFL treatment according to Japanese labeling. Exclusion Criteria: * Patients who are contraindicated based on approved label * Diagnosis of other indication
Where it's running
-
Many locations
Multiple Locations, Japan Recruiting
Study contacts
- Study coordinator: Bayer Clinical Trials Contact
- Email: clinical-trials-contact@bayer.com
- Phone: (+)1-888-84 22937
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Iris Blood Flow Measured by OCTA in Diabetic Eye Disease
This study uses a non-invasive eye scan to see if iris blood flow differs across people with Type 2 diabetes and varying eye complications, including those without eye disease and those with neovascular glaucoma.
-
Intracameral versus intravitreal bevacizumab for neovascular glaucoma
This study will try giving bevacizumab either into the front chamber of the eye (intracameral) or into the vitreous (intravitreal) to see which is safer and better at lowering eye pressure for adults with neovascular glaucoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.